Search bioRxiv⌕ Search

Biology subjects

Madni, Z. K.

Publications and source records attributed to Madni, Z. K..

2 recordsLinked to original sources

Immunologic insights into the critical epitopes of HIV-1 and structure-based characterization of cross-reactive antibodies

HIV-1 escape from neutralizing antibodies even in the presence of strong host immunity is associated with variations in envelope proteins that drive antigenic diversification. The virus exploits the error-prone nature of reverse transcriptase and the high mutation rate as key survival strategies. However, the rate of production of new variations occurs at relatively slow pace. Interestingly, the immune system often produces cross-reactive antibodies, with anticipated role in neutralizing point mutations in HIV surface proteins by cross-reacting with mutants and tolerating them. In light of this paradox, we explored the mystery of immune evasion and antibody promiscuity by screening single chain variable fragment (scFvs) antibodies against several crucial HIV-1 gp41 epitopes using a phage display library. These findings underscore the broader significance of cross-reactive antibodies. Here, high-affinity cross-reactive scFvs showed physiologically relevant affinities with peptide epitopes, their analogs, and the native HIV-1 gp41 protein. We determined the crystal structure of a high-affinity cross-reactive scFv, DE94, and obtained insights into the molecular interactions of scFv antibodies with peptide epitopes and its natural mutants using molecular docking studies. This analysis of cross-reactive antibodies could contribute to the therapeutic development against immune-evading pathogens and paves the way for innovative strategies for combating viral infections, including emerging global threats.

biophysics↗

Antibodies against Elapidae and Viperidae snake venoms: in vivo neutralization and mechanistic insights

Snake envenomation results in a range of clinical sequelae, and effective therapy is yet to be discovered. Anti-snake venom antibodies are being considered as a potent strategy. We developed venom-neutralizing humanized antibody scFvs and elucidated biochemical and structural mechanisms associated with the inhibition of toxicity. Tomlinson I and J human antibody scFv libraries were screened against Naja naja and Echis carinatus venoms, and seven unique antibody scFvs were obtained. Further, specific toxins of snake venom interacting with each of these scFvs were identified, and phospholipase A2 (PLA2) was found to be prominently captured by the phage-anchored antibody scFvs. Proteomic analysis of whole venom also revealed PLA2 to be the most abundant toxin in both venom samples. The scFvs binding to PLA2 were used to perform in vivo survival assay using the mouse model and in vitro toxin inhibition assays. scFv N194, which binds to acidic PLA2, showed considerable survival in Naja naja venom-challenged mice and conferred up to 50% protection. A combination of two scFvs, E113 and E10, both interacting with basic PLA2, exhibited synergistically enhanced survival of 33% in Echis carinatus venom-challenged mice, compared to 16% survival conferred by an equal amount of individual scFvs. Furthermore, these scFvs demonstrated inhibition of venom-induced myotoxicity and hemolysis which corroborate the survival data. Structural studies highlighted possible modes of PLA2 neutralization by scFv through the engagement of CDRs with C-terminal myotoxic loop and interfacial region, which are crucial for PLA2 toxicity.

biochemistry↗